Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Bendamustine hydrochloride
État du projet:
Terminé
Domaine thérapeutique:
Non-Hodgkin Lymphoma and Mantle Cell Lymphoma
Fabricant:
Lundbeck Canada Inc.
Brand Name:
Treanda
Gamme de produits:
Examen en vue du remboursement
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
25 mg/vial and 100 mg/vial
Tumour Type:
Lymphoma
Indications:
Non-Hodgkin lymphoma (NHL)
Funding Request:
For patients with indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (first line and relapse/refractory)
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Lundbeck Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Couvrir le remboursement
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016